CSNpharm
Lumiracoxib is a COX2 selective inhibitor and a non-steroidal anti-inflammatory drug (NSAID), which inhibits COX2 with IC50 and Ki values of 0.14 μM and 0.06 μM and inhibits COX1 with Ki of 3 μM.
More Information
Supplier Page
CSNpharm
Lumiracoxib is a COX2 selective inhibitor and a non-steroidal anti-inflammatory drug (NSAID), which inhibits COX2 with IC50 and Ki values of 0.14 μM and 0.06 μM and inhibits COX1 with Ki of 3 μM.
More Information
Supplier Page
CSNpharm
Lumiracoxib is a COX2 selective inhibitor and a non-steroidal anti-inflammatory drug (NSAID), which inhibits COX2 with IC50 and Ki values of 0.14 μM and 0.06 μM and inhibits COX1 with Ki of 3 μM.
More Information
Supplier Page
CSNpharm
Lumiracoxib is a COX2 selective inhibitor and a non-steroidal anti-inflammatory drug (NSAID), which inhibits COX2 with IC50 and Ki values of 0.14 μM and 0.06 μM and inhibits COX1 with Ki of 3 μM.
More Information
Supplier Page
CSNpharm
Lupalbigenin, a natural product isolated and purified from the roots of Glycyrrhiza uralensis Fisch, sensitizes detachment-induced cell death in human lung cancer cell through down-regulation of pro-survival proteins, and shows promising cytotoxic effects toward HL-60 cells.
More Information
Supplier Page
CSNpharm
Lupalbigenin, a natural product isolated and purified from the roots of Glycyrrhiza uralensis Fisch, sensitizes detachment-induced cell death in human lung cancer cell through down-regulation of pro-survival proteins, and shows promising cytotoxic effects toward HL-60 cells.
More Information
Supplier Page
CSNpharm
Lupanine, a natural product isolated and purified from the herbs of Cytisus scoparius, has antimicrobial activity and a weak sedative effect on the central nervous system, interaction with specific drugs used for treatment of the CNS and for analgesic activity.
More Information
Supplier Page
CSNpharm
Lupanine, a natural product isolated and purified from the herbs of Cytisus scoparius, has antimicrobial activity and a weak sedative effect on the central nervous system, interaction with specific drugs used for treatment of the CNS and for analgesic activity.
More Information
Supplier Page
CSNpharm
Lutein is a natural product isolated and purified from the herbs of Tagetes erecta with antitumour, antimutagenic and a wide range of antimicrobial action, and is potentially useful for treating macular degeneration.
More Information
Supplier Page
CSNpharm
Lutein is a natural product isolated and purified from the herbs of Tagetes erecta with antitumour, antimutagenic and a wide range of antimicrobial action, and is potentially useful for treating macular degeneration.
More Information
Supplier Page
CSNpharm
Lutein is a natural product isolated and purified from the herbs of Tagetes erecta with antitumour, antimutagenic and a wide range of antimicrobial action, and is potentially useful for treating macular degeneration.
More Information
Supplier Page
CSNpharm
Lutein is a natural product isolated and purified from the herbs of Tagetes erecta with antitumour, antimutagenic and a wide range of antimicrobial action, and is potentially useful for treating macular degeneration.
More Information
Supplier Page
CSNpharm
Lutein is a natural product isolated and purified from the herbs of Tagetes erecta with antitumour, antimutagenic and a wide range of antimicrobial action, and is potentially useful for treating macular degeneration.
More Information
Supplier Page
CSNpharm
Lutein is a natural product isolated and purified from the herbs of Tagetes erecta with antitumour, antimutagenic and a wide range of antimicrobial action, and is potentially useful for treating macular degeneration.
More Information
Supplier Page
CSNpharm
Luteolin is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Kis of 15.0/6.4/13.9/11.1/9.5 μM, respectively, it is a flavonoid found in Terminalia chebula.
More Information
Supplier Page
CSNpharm
Luteolin is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Kis of 15.0/6.4/13.9/11.1/9.5 μM, respectively, it is a flavonoid found in Terminalia chebula.
More Information
Supplier Page
CSNpharm
Luteolin is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Kis of 15.0/6.4/13.9/11.1/9.5 μM, respectively, it is a flavonoid found in Terminalia chebula.
More Information
Supplier Page
CSNpharm
Luteollin 5-glucoside is a natural product isolated and purified from the herb of Dracocephalum ruyschiana L. with antioxidant activity, which can inhibit lipid peroxidation, and has DPPH radical-scavenging activity.
More Information
Supplier Page
CSNpharm
Luteollin 5-glucoside is a natural product isolated and purified from the herb of Dracocephalum ruyschiana L. with antioxidant activity, which can inhibit lipid peroxidation, and has DPPH radical-scavenging activity.
More Information
Supplier Page
CSNpharm
Luteone is a natural product isolated and purified from the herbs of Erythrina variegata Linn., possessing antifungal activity sufficient to support its proposed role as pre-infectional resistance factors.
More Information
Supplier Page
CSNpharm
Luteone is a natural product isolated and purified from the herbs of Erythrina variegata Linn., possessing antifungal activity sufficient to support its proposed role as pre-infectional resistance factors.
More Information
Supplier Page
CSNpharm
LXR-623 is a novel and brain-penetrant LXR agonist with IC50 values of 179 and 24 nM for LXRα and LXRβ, respectively.
More Information
Supplier Page
CSNpharm
LXR-623 is a novel and brain-penetrant LXR agonist with IC50 values of 179 and 24 nM for LXRα and LXRβ, respectively.
More Information
Supplier Page
CSNpharm
LXR-623 is a novel and brain-penetrant LXR agonist with IC50 values of 179 and 24 nM for LXRα and LXRβ, respectively.
More Information
Supplier Page
CSNpharm
LXR-623 is a novel and brain-penetrant LXR agonist with IC50 values of 179 and 24 nM for LXRα and LXRβ, respectively.
More Information
Supplier Page
CSNpharm
LXR-623 is a novel and brain-penetrant LXR agonist with IC50 values of 179 and 24 nM for LXRα and LXRβ, respectively.
More Information
Supplier Page
CSNpharm
LXR-623 is a novel and brain-penetrant LXR agonist with IC50 values of 179 and 24 nM for LXRα and LXRβ, respectively.
More Information
Supplier Page
CSNpharm
LY 404187 is a selective positive allosteric modulator of AMPA receptors with IC50s of 0.15, 0.21, 1.66 and 5.65 μM for GluA2i, GluA4i, GluA3i and GluA1i respectively.
More Information
Supplier Page
CSNpharm
LY 404187 is a selective positive allosteric modulator of AMPA receptors with IC50s of 0.15, 0.21, 1.66 and 5.65 μM for GluA2i, GluA4i, GluA3i and GluA1i respectively.
More Information
Supplier Page
CSNpharm
LY 404187 is a selective positive allosteric modulator of AMPA receptors with IC50s of 0.15, 0.21, 1.66 and 5.65 μM for GluA2i, GluA4i, GluA3i and GluA1i respectively.
More Information
Supplier Page
CSNpharm
LY 404187 is a selective positive allosteric modulator of AMPA receptors with IC50s of 0.15, 0.21, 1.66 and 5.65 μM for GluA2i, GluA4i, GluA3i and GluA1i respectively.
More Information
Supplier Page
CSNpharm
High affinity inhibitor of phenylethanolamine-N-methyltransferase (PNMT) (Ki = 0.09 μM in vitro). Suppresses the release of growth hormone in an in vivo rat model.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
LY255283 is selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 μM at human recombinant BLT2 and BLT1 receptors respectively), and inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration.
More Information
Supplier Page
CSNpharm
LY255283 is selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 μM at human recombinant BLT2 and BLT1 receptors respectively), and inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration.
More Information
Supplier Page
CSNpharm
LY255283 is selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 μM at human recombinant BLT2 and BLT1 receptors respectively), and inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration.
More Information
Supplier Page
CSNpharm
LY255283 is selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 μM at human recombinant BLT2 and BLT1 receptors respectively), and inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration.
More Information
Supplier Page
CSNpharm
LY255283 is selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 μM at human recombinant BLT2 and BLT1 receptors respectively), and inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays.
More Information
Supplier Page
CSNpharm
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays.
More Information
Supplier Page
CSNpharm
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays.
More Information
Supplier Page